Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

12.09.2018 | original article | Ausgabe 6/2018

Spektrum der Augenheilkunde 6/2018

Long-term follow-up of half-fluence photodynamic therapy in acute central serous chorioretinopathy

Spektrum der Augenheilkunde > Ausgabe 6/2018
MD Eva Smretschnig, MD Stefan Hagen, BSc Jutta Gamper, MD Ilse Krebs, MD Susanne Binder, MD Siamak Ansari-Shahrezaei
Wichtige Hinweise

Authors’ contributions

Design of the study (E. Smretschnig, S. Ansari-Shahrezaei), conduct of the study (E. Smretschnig, S. Hagen, J. Gamper, I. Krebs, S. Binder, S. Ansari-Shahrezaei), data collection and management (E. Smretschnig, S. Hagen), analysis (E. Smretschnig, J. Gamper, S. Ansari-Shahrezaei), interpretation (E. Smretschnig, S. Hagen, I. Krebs, S. Binder, S. Ansari-Shahrezaei), preparation (E.S, S. Ansari-Shahrezaei), review and final approval (E. Smretschnig, S. Hagen, I. Krebs, J. Gamper, S. Binder, S. Ansari-Shahrezaei)



To evaluate the long-term results of indocyanine green angiography(ICGA)-guided verteporfin (Visudyne®, Novartis, Basel, Switzerland) photodynamic therapy (PDT) with half-fluence rate in the treatment of acute symptomatic central serous chorioretinopathy (CSC).

Material and methods

A retrospective review was performed of 12 patients with acute symptomatic CSC verified by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA), treated with ICGA-guided verteporfin (6 mg/m2)-PDT with half-fluence rate (25 J/cm2). The vision-related quality of life (VR QOL) 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) was completed by all patients and 82 controls.


Best corrected visual acuity (BCVA) at baseline was 77.5 (±10; n = 12) according to the Early Treatment Diabetic Retinopathy Study (EDTRS) letter score and changed to 89 letters (±9.9; p = 0.0003) at long-term follow-up (83.8 ± 4.8 months after PDT). Baseline contrast sensitivity (CS) was 29.5 ± 4.5 Pelli–Robson letters and increased to 34.5 ± 4.5 letters at long term (p < 0.0006). Baseline central foveal thickness (CFT) was 419 μm and decreased to 242 µm at long term (p < 0.0001). The long-term vision-related quality of life of patients was similar to that of controls.


ICGA-guided half-fluence PDT with verteporfin results in excellent long-term visual improvement in BCVA and CS, a significant reduction of CFT, and high levels of VR QOL.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 6/2018

Spektrum der Augenheilkunde 6/2018 Zur Ausgabe